AbbVie Inc. $ABBV Shares Sold by D.A. Davidson & CO.

Key Points

• D.A. Davidson reduced its AbbVie stake by 10.6% in the second quarter, selling 28,907 shares and retaining 243,700 shares valued at approximately $61.3 million. Institutional investors collectively own 70.23% of ABBV.
• AbbVie reported quarterly earnings of $3.65 per share and revenue of $16.99 billion, exceeding analyst estimates, while revenue rose 10.2% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $275.73.
• AbbVie completed a multibillion-dollar debt offering to help finance its acquisition of Apogee Therapeutics, expanding its immunology portfolio but increasing leverage and interest-cost considerations for investors.

D.A. Davidson & CO. reduced its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 10.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 243,700 shares of the company's stock after selling 28,907 shares during the quarter. D.A. Davidson & CO.'s holdings in AbbVie were worth $61,325,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in AbbVie in the fourth quarter valued at about $5,865,055,000. Wellington Management Group LLP lifted its holdings in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Capital World Investors boosted its position in shares of AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company's stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares during the period. Cardano Risk Management B.V. increased its holdings in AbbVie by 914.6% in the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie completed a multibillion-dollar senior notes offering to help finance its acquisition of Apogee Therapeutics. The transaction provides funding for the deal and supports AbbVie’s strategy of expanding its immunology and specialty medicines portfolio as it seeks new growth opportunities. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition AbbVie Raises $9 Billion Debt to Fund Acquisition
• Neutral Sentiment: The Apogee financing also introduces additional leverage. While debt allows AbbVie to pursue the acquisition without issuing equity, investors will assess the impact of higher interest costs and whether Apogee’s pipeline generates sufficient returns to justify the transaction. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition
• Neutral Sentiment: AbbVie announced its 2026 Immunology Scholarship recipients, continuing a 10-year community-support program. The announcement reinforces corporate reputation but is unlikely to materially affect earnings or the stock’s near-term valuation. AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients
• Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million, reducing his holdings by about 30.5%. Insider sales can reflect personal financial planning, but the sizable transaction may create a modest negative sentiment signal for investors. AbbVie Insider Transaction

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ABBV. Citigroup lifted their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Wednesday, July 15th. Evercore set a $235.00 target price on AbbVie in a report on Friday, May 15th. UBS Group lifted their target price on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research report on Monday, July 13th. Barclays boosted their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Finally, Piper Sandler reissued an "overweight" rating and issued a $298.00 price objective on shares of AbbVie in a research note on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $275.73.

AbbVie Stock Up 2.6%

Shares of ABBV opened at $265.63 on Thursday. The stock has a 50 day moving average price of $246.98 and a 200 day moving average price of $226.95. The company has a market capitalization of $469.31 billion, a price-to-earnings ratio of 75.04, a price-to-earnings-growth ratio of 0.86 and a beta of 0.30. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie's payout ratio is 195.48%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source